The treatment of advanced renal cell cancer with high-dose oral thalidomide

Stebbing, Justin; Benson, Charlotte; Eisen, Timothy; Pyle, L; Smalley, Keiran S.M.; Bridle, Helen; Mak, Ian; Sapunar, Francisco; A’Hern, Roger; Gore, M.

doi:10.1038/sj.bjc.6692025

Cited by 29 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibitory effects of thalidomide on tumors have been reported in preclinical models [2] and in human clinical trials [9, 27–32]. Favorable results in patients, ranging from partial responses, to disease stabilization, to tumor regression have been reported for multiple myeloma [9, 27], AIDS-related Kaposi’s sarcoma [28], high-grade gliomas [29], hepatocellular carcinoma [30], renal cell carcinoma [31, 32], and advanced melanoma [31].…”

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers

et al. 2008

View full text Add to dashboard Cite

Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors. After a 1-week, three-dose course of thalidomide, the mean MRI-assayed endothelial transfer coefficient, KPS, decreased significantly (p<0.05) from 19.4±9.1 to 6.3±9.1 μl/min·100 cm3. Correspondingly, microscopic measurements of extravasated MMCM, expressed as fractional area of streptavidin staining, were significantly (p<0.05) lower in thalidomide-treated tumors (18.6±11.9%) than in control saline-treated tumors (50.2±2.3%). On a tumor-by-tumor basis, post-treatment KPS values correlated significantly (r2=0.55, p<0.05) with microscopic measures of MMCM extravasation. However, no significant differences were observed between saline- and thalidomide-treated tumors with respect to rate of growth, vascular richness, or amount of VEGF-containing cells. Because of its sensitivity to the detection of changes in vascular leakage in tumors, this MMCM-enhanced MRI assay could prove useful for monitoring the effects of thalidomide on an individual patient basis. The significant correlation between MRI and fluorescence microscopic measures of MMCM extravasation supports the utility of the non-invasive MRI approach for assessing the action of thalidomide on tumor blood vessels.

show abstract

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers

et al. 2008

View full text Add to dashboard Cite

show abstract

“…148 Several trials of thalidomide in advanced RCC have been reported. [149][150][151][152] Patients receiving 200 mg/day or less orally tolerated thalidomide well. The objective response rate was between 0% (0/25) and 10% (2/20).…”

Section: Thalidomidementioning

confidence: 99%

Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

2006

View full text Add to dashboard Cite

Angiogenesis is considered a prerequisite for solid tumor growth. Antiangiogenic therapy reduces tumor size and extends host survival in a number of preclinical animal models. However, in humans antiangiogenic therapy is a poor promoter of tumor regression and has shown minimal effect on patient survival. In urinary cancers, such as renal cell cancer, prostate cancer, and bladder cancer, advanced refractory disease is a good candidate for antiangiogenic therapy because of its resistance to ordinary chemotherapy, radiotherapy, and hormonal therapy. Unique characteristics of molecular mechanisms underlie the induction of angiogenesis in urinary cancers. In this review, we summarize these unique mechanisms and review the results of clinical trials of antiangiogenic therapy for these cancers, discussing prospects and problems relating to antiangiogenic therapy.

show abstract

“…In kidney cancer, thalidomide as a single agent has demonstrated stabilization of tumor growth in patients with advanced disease with only a very small number of patients experiencing a partial tumor response [28]. The dosing of thalidomide used in these studies has ranged from 100 to 1200 mg daily.…”

Section: Thalidomidementioning

confidence: 99%

Chemotherapies and immunotherapies for metastatic kidney cancer

Atkins

2005

Curr Urol Rep

View full text Add to dashboard Cite

Most patients who develop kidney cancer are effectively treated with a radical nephrectomy; however, for those patients who present with or develop metastatic disease, the therapeutic options are limited. Interferon and interleukin-2 remain the standard therapies. Several studies have identified the optimal doses and schedules of these cytokines and groups of patients most likely to benefit from immunotherapy. Although cytotoxic chemotherapy continues to have a minor role in patients with clear cell renal carcinoma, it may become the treatment of choice for some patients with variant renal cancers. Novel agents targeting the vascular endothelial growth factor, its receptor, and other hypoxia-induced proteins are showing great promise and soon may expand the therapeutic options for patients with advanced kidney cancer.

show abstract

The treatment of advanced renal cell cancer with high-dose oral thalidomide

Cited by 29 publications

References 14 publications

Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers

Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers

Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

Chemotherapies and immunotherapies for metastatic kidney cancer

Contact Info

Product

Resources

About